高剂量司美格鲁肽(最高16 mg)用于2型糖尿病合并超重或肥胖人群:一项随机、安慰剂对照的2期试验
该2期试验纳入245例接受二甲双胍治疗、BMI≥27 kg/m²的2型糖尿病伴超重或肥胖个体,随机接受每周司美格鲁肽2、8或16 mg皮下注射或安慰剂治疗40周。16 mg与2 mg相比,HbA1c降幅差异未达统计学显著,体重降幅差异有统计学意义但幅度有限,且8和16 mg组不良事件及因不良事件停药更频繁。
要点
- 16 mg与2 mg相比HbA1c变化差异为-0.3个百分点(95%CI -0.7至0.2;P=0.245),未达统计学显著。
- 16 mg与2 mg相比体重变化差异为-3.4 kg(95%CI -6.0至-0.8;P=0.011),降幅有统计学意义。
- 8和16 mg组治疗中出现的不良事件及因不良事件停药(主要为胃肠道)比2 mg组更频繁。
核心结论
- 在2型糖尿病合并超重或肥胖人群中,较高剂量司美格鲁肽提供适度的额外降糖作用,并带来额外体重下降,代价是更多不良事件和治疗中断。
- 一项评估高剂量司美格鲁肽用于肥胖的研究目前正在进行中。
研究设计与样本
- 平行分组、参与者和研究者盲法的2期试验,245例接受二甲双胍治疗、BMI≥27 kg/m²的2型糖尿病个体随机接受每周司美格鲁肽2、8或16 mg皮下注射或安慰剂治疗40周。
- 剂量每4周递增,随后进入维持期,不允许调整剂量。
- 主要和次要疗效终点分别为第40周HbA1c和体重较基线的变化。
主要发现
- 16 mg与2 mg相比,HbA1c变化的估计治疗差异为-0.3个百分点(95%CI -0.7至0.2;P=0.245),体重变化的估计治疗差异为-3.4 kg(95%CI -6.0至-0.8;P=0.011),基于治疗策略估计目标。
- 16 mg与2 mg相比,基于假设估计目标,HbA1c变化的估计治疗差异为-0.5个百分点(95%CI -1.0至-0.1;P=0.015),体重变化的估计治疗差异为-4.5 kg(95%CI -7.6至-1.4;P=0.004)。
- 剂量-反应模型证实了上述发现。
- 司美格鲁肽8和16 mg组治疗中出现的不良事件及因不良事件停药(主要为胃肠道)比2 mg组更频繁。
- 未报告严重低血糖事件。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Studies have demonstrated dose-dependent efficacy of glucagon-like peptide 1 receptor agonists for glycemic control and body weight. The aim of this trial was to characterize the dose-dependent effects of semaglutide (up to 16 mg/week) in people with type 2 diabetes and overweight or obesity. RESEARCH DESIGN AND METHODS: In this parallel-group, participant- and investigator-blinded, phase 2 trial, 245 individuals with type 2 diabetes and BMI ≥27 kg/m2 on metformin were randomized to weekly semaglutide (2, 8, or 16 mg s.c.) or placebo for 40 weeks. Doses were escalated every 4 weeks, followed by a maintenance period. Dose modifications were not allowed. Primary and secondary efficacy end points included change from baseline to week 40 in HbA1c and body weight, respectively. RESULTS: Estimated treatment difference between 16 and 2 mg was -0.3 percentage points (%-points) (95% CI -0.7 to 0.2; P = 0.245) for HbA1c change and -3.4 kg (-6.0 to -0.8; P = 0.011) for weight change for the treatment policy estimand and -0.5%-points (-1.0 to -0.1; P = 0.015) and -4.5 kg (-7.6 to -1.4; P = 0.004), respectively, for the hypothetical estimand. Dose-response modeling confirmed these findings. Treatment-emergent adverse events (AEs) and treatment discontinuations due to AEs, primarily gastrointestinal, were more frequent in the semaglutide 8 and 16 mg groups than in the 2 mg group. No severe hypoglycemic episodes were reported. CONCLUSIONS: Higher semaglutide doses for type 2 diabetes and overweight or obesity provide modest additional glucose-lowering effect, with additional weight loss, at the expense of more AEs and treatment discontinuations. A study for evaluating high-dose semaglutide in obesity is currently underway.
引用
- Aroda VR, Jørgensen NB, Kumar B, et al. High-Dose Semaglutide (Up to 16 mg) in People With Type 2 Diabetes and Overweight or Obesity: A Randomized, Placebo-Controlled, Phase 2 Trial. Diabetes Care. 2025. PMID: 40279144. doi:10.2337/dc24-2425
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。